Phaseline

Targets › MC1R

MC1R (Melanocyte-stimulating hormone receptor): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 2; Immunology; next expected readout Feb 2027.

G protein-coupled receptor that binds melanocyte-stimulating hormones (alpha, beta, and gamma-MSH) and adrenocorticotropic hormone/ACTH, which are peptide products of the POMC precursor protein. Upon activation, MC1R couples with the G(s) protein, stimulating adenylate cyclase and activating the cAMP-dependent signaling pathway. (UniProt, Q01726)

Open in Phaseline: the race on MC1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tanabe PharmaDersimelagon (MT-7117)
Melanocortin receptor 1 agonist
MC1RPhase 3EPPDec 2027
ClinuvelAfamelanotide
Melanocortin receptor 1 agonist
MC1RPhase 3Vitiligo–
Hudson BiotechAfamelanotide
Melanocortin receptor 1 agonist
MC1RPhase 2NonSegmental VitiligoFeb 2027

Conditions

NonSegmental Vitiligo (1) Vitiligo (1) EPP (1)

Modalities

small molecule (2), protein or peptide (1)

Companies

Hudson Biotech (1) Clinuvel (1) Tanabe Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.